John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Metastatic colorectal cancers: A step-up strategy in a palliative setting? Volume 26, issue 1, Janvier 2019

  • [1] Jooste V., Remontet L., Colonna M. Trends in the incidence of digestive cancers in France between 1980 and 2005 and projections for the year 2010. Eur J Prev. 2011;20:375-380.
  • [2] Ferlay J., Shin H.R., Bray F. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917.
  • [3] Remontet L., Estève J., Bouvier A.M. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique. 2003;51:3-30.
  • [4] Faivre J., Bossard N., Jooste V. Trends in net survival from colon cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J of Cancer Prev. 2017;26:S40-S47. the GRELL EUROCARE-5 Working Group
  • [5] Benoist S., Brouquet A., Penna C. Complete response of colorectal liver metastases after chemotherapy : does it mean cure? J Clin Oncol. 2006;24:3939-3945.
  • [6] Grothey A., Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23:9441-9442.
  • [7] Cunningham D., Humblet Y., Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
  • [8] Van Cutsem E., Köhne C.H., Lang I. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line Ttreatment for metastatic colorectal cancer : updated analysis of overall survival according to tumor and mutation status. J Clin Oncol. 2011;29:2011-2019. KRAS BRAF
  • [9] Bokemeyer C., Bondarenko I., Hartmann J.T. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22:1535-1546.
  • [10] Hurwitz H., Fehrenbacher L., Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
  • [11] Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007 ; 370 : 135-42.
  • [12] Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS) : a randomised controlled trial. Lancet 2007 ; 370 : 143-52.
  • [13] Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011 ; 12 : 1032-44.
  • [14] Jin S, Pazdur R, Sridhara R, et al. Re-Evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol 2017 ; 35 : 3745-52.
  • [15] Cunningham D, Sirohi B, Pluzanska A, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009 ; 20 : 244-50.
  • [16] Seymour M.T., Thompson L.C., Wasan H.S. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open label, randomised factorial trial. Lancet. 2011;377:1749-1759.
  • [17] Aparicio T., Lavau-Denes S., Phelip J.M. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). Ann Oncol. 2016;27:121-127.
  • [18] Aparicio T., Jouve J.L., Teillet L. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-Line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31:1464-1470.
  • [19] Boige V., Mendiboure J., Pignon J.P. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28:2556-2564.
  • [20] Tebbutt N.C., Wilson K., Gebski V.J. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer : results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28:3191-3198.
  • [21] Cunningham D., Lang I., Marcuello E., Lorusso V. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077-1085.
  • [22] Aparicio T., Bouché 0, Taieb J. Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial - PRODIGE 20 study results. Ann Oncol. 2018;29:133-139.
  • [23] Aparicio T., Pamoukdjianb F., Queroc L. Colorectal cancer care in elderly patients: unsolved issues. Digestive and Liver Disease. 2016;48:1112-1118.
  • [24] Phelip JM, Benhaim L, Bouché O, et al. Cancer colorectal métastatique. Thésaurus National de Cancérologie Digestive, Février 2018, [En ligne].[http://www.tncd.org].
  • [25] Van Cutsem E., Cervantes A., Adam R. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-1422.